120 related articles for article (PubMed ID: 26717601)
61. Behaviour of estrogen receptor, histological correlation, and clinical outcome in patients with benign breast disorders.
Khanna AK; Tapodar JK; Khanna HD; Khanna S; Khanna A
Eur J Surg; 2002; 168(11):631-4. PubMed ID: 12699101
[TBL] [Abstract][Full Text] [Related]
62. Inhibition of tumor angiogenesis by angiostatin: from recombinant protein to gene therapy.
Dell'Eva R; Pfeffer U; Indraccolo S; Albini A; Noonan D
Endothelium; 2002; 9(1):3-10. PubMed ID: 12901356
[TBL] [Abstract][Full Text] [Related]
63. Limited plasmin proteolysis of vitronectin. Characterization of the adhesion protein as morpho-regulatory and angiostatin-binding factor.
Kost C; Benner K; Stockmann A; Linder D; Preissner KT
Eur J Biochem; 1996 Mar; 236(2):682-8. PubMed ID: 8612645
[TBL] [Abstract][Full Text] [Related]
64. Human gross cyst breast disease and cystic fluid: bio-molecular, morphological, and clinical studies.
Mannello F; Tonti GA; Papa S
Breast Cancer Res Treat; 2006 May; 97(2):115-29. PubMed ID: 16331347
[TBL] [Abstract][Full Text] [Related]
65. Elevated levels of urine angiostatin and plasminogen/plasmin in cancer patients.
Cao Y; Veitonmaki N; Keough K; Cheng H; Lee LS; Zurakowski D
Int J Mol Med; 2000 May; 5(5):547-51. PubMed ID: 10762660
[TBL] [Abstract][Full Text] [Related]
66. Therapeutic potential of angiostatin in diabetic nephropathy.
Zhang SX; Wang JJ; Lu K; Mott R; Longeras R; Ma JX
J Am Soc Nephrol; 2006 Feb; 17(2):475-86. PubMed ID: 16394111
[TBL] [Abstract][Full Text] [Related]
67. Pathological profile of patients with breast diseases in Shiraz.
Rezaianzadeh A; Sepandi M; Akrami M; Tabatabaee H; Rajaeefard A; Tahmasebi S; Talei A
Asian Pac J Cancer Prev; 2014; 15(19):8191-5. PubMed ID: 25339004
[TBL] [Abstract][Full Text] [Related]
68. Tumor-associated overexpression of the soluble T1-S receptor in lymph node-negative breast cancer.
Werenskiold AK; Prechtel D; Harbeck N; Höfler H
Diagn Mol Pathol; 2000 Mar; 9(1):26-34. PubMed ID: 10718210
[TBL] [Abstract][Full Text] [Related]
69. Malignant ascites fluid (MAF), including ovarian-cancer-associated MAF, contains angiostatin and other factor(s) which inhibit angiogenesis.
Richardson M; Gunawan J; Hatton MW; Seidlitz E; Hirte HW; Singh G
Gynecol Oncol; 2002 Sep; 86(3):279-87. PubMed ID: 12217749
[TBL] [Abstract][Full Text] [Related]
70. Angiostatin.
Cao Y; Xue L
Semin Thromb Hemost; 2004 Feb; 30(1):83-93. PubMed ID: 15034800
[TBL] [Abstract][Full Text] [Related]
71. Generation of biologically active angiostatin kringle 1-3 by activated human neutrophils.
Scapini P; Nesi L; Morini M; Tanghetti E; Belleri M; Noonan D; Presta M; Albini A; Cassatella MA
J Immunol; 2002 Jun; 168(11):5798-804. PubMed ID: 12023382
[TBL] [Abstract][Full Text] [Related]
72. Sarcoglycans in the normal and pathological breast tissue of humans: an immunohistochemical and molecular study.
Arco A; Favaloro A; Gioffrè M; Santoro G; Speciale F; Vermiglio G; Cutroneo G
Cells Tissues Organs; 2012; 195(6):550-62. PubMed ID: 22067288
[TBL] [Abstract][Full Text] [Related]
73. Characterization of female breast lesions from multi-wavelength time-resolved optical mammography.
Spinelli L; Torricelli A; Pifferi A; Taroni P; Danesini G; Cubeddu R
Phys Med Biol; 2005 Jun; 50(11):2489-502. PubMed ID: 15901950
[TBL] [Abstract][Full Text] [Related]
74. Angiostatin directly inhibits human prostate tumor cell invasion by blocking plasminogen binding to its cellular receptor, CD26.
Gonzalez-Gronow M; Grenett HE; Gawdi G; Pizzo SV
Exp Cell Res; 2005 Feb; 303(1):22-31. PubMed ID: 15572024
[TBL] [Abstract][Full Text] [Related]
75. Significance of resistive index in color Doppler ultrasonogram: differentiation between benign and malignant breast masses.
Choi HY; Kim HY; Baek SY; Kang BC; Lee SW
Clin Imaging; 1999; 23(5):284-8. PubMed ID: 10665344
[TBL] [Abstract][Full Text] [Related]
76. Fibroadenoma of the breast: analysis of associated pathological entities--a different risk marker in different age groups for concurrent breast cancer.
Shabtai M; Saavedra-Malinger P; Shabtai EL; Rosin D; Kuriansky J; Ravid-Megido M; Ben Haim M; Ayalon AH
Isr Med Assoc J; 2001 Nov; 3(11):813-7. PubMed ID: 11729575
[TBL] [Abstract][Full Text] [Related]
77. Inhibitory effect of angiostatins on activity of the plasminogen/plasminogen activator system.
Aisina RB; Mukhametova LI; Gulin DA; Levashov MY; Prisyazhnaya NV; Gershkovich KB; Varfolomeyev SD
Biochemistry (Mosc); 2009 Oct; 74(10):1104-13. PubMed ID: 19916923
[TBL] [Abstract][Full Text] [Related]
78. Cystic fibroadenoma of the breast: a case report.
Durak MG; Karaman I; Canda T; Balci P; Harmancioğlu O
Turk Patoloji Derg; 2011; 27(3):254-6. PubMed ID: 21935877
[TBL] [Abstract][Full Text] [Related]
79. Differential conversion of plasminogen to angiostatin by human corneal cell populations.
Warejcka DJ; Vaughan KA; Bernstein AM; Twining SS
Mol Vis; 2005 Oct; 11():859-68. PubMed ID: 16270025
[TBL] [Abstract][Full Text] [Related]
80. Elevated matrix metalloprotease and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization.
Pozzi A; Moberg PE; Miles LA; Wagner S; Soloway P; Gardner HA
Proc Natl Acad Sci U S A; 2000 Feb; 97(5):2202-7. PubMed ID: 10681423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
